Oncology Fellow @DanaFarber and @MGHCancerCenter | @Forbes 30 Under 30 | oncology precision medicine
Joined February 2020
- Tweets 72
- Following 376
- Followers 805
- Likes 513
13 Photos and videos
Pinned Tweet
28 Apr 2025
How should we be drugging RAS and developing clinical combinations for RAS-driven tumors?
@andrewaguirremd, Alice Shaw, @Julien__Dilly, and I have a lot of thoughts (>15,000 words of thoughts), and our mega review is out now at @CD_AACR! Check it out: shorturl.at/ojplo
28 Apr 2025
Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker @andrewaguirremd: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw
3
20
2,926
Last year, we reported that KRAS PRMT5 is synergistic in MTAP-null PDAC (doi.org/10.1158/0008-5472.CA…). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.
RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD
24 Jul 2025
Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
doi.org/10.1158/0008-5472.CA…
2
42
149
35,534
Absolutely incredible to see the massive benefit of RAS inhibition in pancreatic cancer patients, changing the field as I finish my training!! Led by one of my clinical mentors, Brian Wolpin, and received with standing ovation.
Also very cool to be cited in the discussion :)
1
3
59
5,916
Richard Y. Ebright, MD, PhD retweeted
Incredible #ASCO26 moment.
Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD
16
136
990
154,179
A new standard for PDAC. Daraxonrasib with 13.2m OS in 2L, and next-generation molecules in development. #RAS
Incredible to see this field changing as I finish training.
Congrats to $RVMD, @NextechInvest @schroederthilo, and to all the patients!!!
tinyurl.com/4jx88ae8
1
326
24 Jul 2025
Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
doi.org/10.1158/0008-5472.CA…
3
16
20,628
3 Jun 2025
So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible @DanaFarber co-fellows 🌟🌟🌟
@SaraKCharMD @SWaliany @tess_omeara @AshleyOdai
1
4
31
2,505
Richard Y. Ebright, MD, PhD retweeted
2 Jun 2025
No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO
6
6
66
2,922
16 May 2025
Disgusting.
16 May 2025
The Trump administration has moved to terminate scores of research grants at Harvard University and its medical school, imperiling scores of research projects and potentially upending the futures of dozens of young scientists. trib.al/jdPxQh1
2
403
Richard Y. Ebright, MD, PhD retweeted
27 Dec 2023
56 FDA/CDER novel drug approvals in 2023 ( 51% from 2022)
Accelerated approval: 9
Orphan drug designations: 18
Fast track designation: 16
Priority review: 24
Breakthrough therapy: 9
3
21
92
11,384
30 Nov 2023
Congrats to the next wave of @DanaFarber / @MGHCancerCenter fellows!! An incredible group coming from @mghmedres! @MattMeiz @DylanJMartini @ben_ouyang @SiennaDurbin
3
9
96
16,365
Richard Y. Ebright, MD, PhD retweeted
5 Jul 2023
So excited to start heme/onc fellowship @DanaFarber / @MGHCancerCenter with this phenomenal crew!
Grateful to my family, friends & mentors @StanfordDeptMed @Ron_Witteles @JoelNealMD @HanZhuMD @HwakeleeMD for helping me reach this next stage of my career
6
103
18,769
24 Jun 2023
Beyond grateful to have had the opportunity to pursue residency at @MGHMedicine with the incredible mentors and coresidents at @mghmedres—so much growth and learning over the last few years.
Per my superlative, maybe one day I’ll put these lessons to use in my Ibiza-based lab 😂
6
1
83
12,648
Richard Y. Ebright, MD, PhD retweeted
6 Apr 2023
Congratulations to @MGBUnited on organizing their union with @cirseiu. I call on @MassGenBrigham to hold a fair and transparent election that is free from intimidation.
4 Apr 2023
It's official! MGB Housestaff United has filed for an election with the National Labor Relations Board!
We are voting YES!
39
162
879
512,075
Richard Y. Ebright, MD, PhD retweeted
6 Apr 2023
Congratulations to @MGBUnited residents, interns and fellows for organizing to form a union with @cirseiu! I stand with these workers in their fight for better wages, benefits and work conditions.
wgbh.org/news/local-news/202…
71
130
759
213,474
Residents and fellows at Mass. General Brigham make patients healthier, and unions make our communities stronger. I applaud the MGB Housestaff, who are unionizing through @cirseiu and advocating for better working conditions, resources, and dignity in their work.
4
50
313
57,971
17 Mar 2023
Congrats to all the #MedTwitter folks matching today!! Especially to the new @mghmedres matches, welcome!
1
11
2,899
3 Mar 2023
Our latest work is out now, looking at transcriptomic mechanisms of resistance to immune checkpoint blockade (ICB), focused on the KEAP1/NRF2 stress response pathway!
a🧵
nature.com/articles/s41698-0…
1
1
28
6,370
3 Mar 2023
Excitingly, our work suggests that targeting the KEAP1/NRF2 pathway may synergize with ICB, opening doors for new clinical use cases for NRF2 inhibitors currently in development. 6/
1
3
523
3 Mar 2023
Big congrats to my co-first authors, Doug Fox and Xin Hong, and my PIs Daniel Haber and Shyamala Maheswaran, and many thanks to everyone that worked to get this study published! 7/
@DebattamaSen @MGHCancerCenter
4
542